Free · 13,591 studies indexed

lighttherapyresearch.com is a free index of research on photobiomodulation and light therapy, gathered from the world’s journals and trial registries.

Sections
Eye, Ear & Vision

Navigating the Dry Eye Therapeutic Puzzle: A Mechanism-Based Overview of Current Treatments

Personalized, mechanism-based treatment strategies are essential for optimizing outcomes in DED. Future research should prioritize well-designed, controlled studies to clarify the role of emerging therapies and guide the individualized management of this heterogeneous condition.

Excerpt from the paper’s abstract. Read the full paper for the details.

AI-generated summary

The authors review clinical studies of treatments for dry eye disease grouped by mechanism, including tear replacement, eyelid therapies, anti-inflammatory drugs, biologic tears and nerve-targeted agents. They report that outcomes vary across studies and that randomized data are limited for several therapies. The review concludes that personalized, mechanism-based management is needed and that more rigorous, controlled research is required.

Who or what was studied
Patients with dry eye disease (DED); the abstract does not state the number of studies included.
Limits stated in the abstract
The abstract states that study designs, patient populations and outcome measures are variable and that randomized data are limited for several therapies.

Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.

Abstract

Background/Objectives

Dry eye disease (DED) is a multifactorial condition with complex pathophysiology involving tear film instability, ocular surface inflammation, and nerve dysfunction. This review summarizes current evidence on the different available therapies targeting these mechanisms.

Methods

A review of clinical studies evaluating treatment outcomes for therapies targeting aqueous tear deficiency, Meibomian gland dysfunction, ocular surface inflammation, and ocular pain was conducted, with an emphasis on randomized controlled trials and meta-analyses where available.

Results

Artificial tears provide symptomatic relief with limited impact on tear film stability. Punctal plugs improve tear retention but show variable efficacy across studies. Treatments targeting MGD-such as lipid-based lubricants, eyelid hygiene, thermal pulsation (LipiFlow, iLux), and intense pulsed light (IPL)-demonstrate improvements in gland function, though outcomes vary. Anti-inflammatory agents including cyclosporine, lifitegrast, and short-term corticosteroids improve ocular surface signs, with mixed symptom relief. Biologic therapies like autologous serum tears and platelet-rich plasma show promise for both signs and symptoms, but data remain inconsistent. Nerve-targeted therapies, including oral neuromodulators (gabapentin, antidepressants), botulinum toxin, and transcutaneous nerve stimulation, have shown potential for managing neuropathic ocular pain, although randomized data are limited. Overall, variability in study designs, patient populations, and outcome measures highlights the need for more rigorous research.

Conclusions

Personalized, mechanism-based treatment strategies are essential for optimizing outcomes in DED. Future research should prioritize well-designed, controlled studies to clarify the role of emerging therapies and guide the individualized management of this heterogeneous condition.

Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.

How to read a review: what to check before relying on this kind of research.

Terms in this paper: Dry eye, Inflammation. Each links to its definition in the glossary.

A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.

Related studies